Astria Therapeutics (NASDAQ:ATXS) Stock Passes Above 50-Day Moving Average - Should You Sell?

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.79 and traded as high as $6.13. Astria Therapeutics shares last traded at $5.86, with a volume of 470,476 shares.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ATXS shares. Wedbush reiterated an "outperform" rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, June 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Stock Up 2.7%

The company has a fifty day moving average price of $4.82 and a 200 day moving average price of $6.35. The stock has a market cap of $325.04 million, a PE ratio of -3.08 and a beta of 0.39.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). As a group, research analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Fcpm Iii Services B.V. bought a new stake in Astria Therapeutics in the 4th quarter worth $25,680,000. ADAR1 Capital Management LLC boosted its holdings in shares of Astria Therapeutics by 605.3% during the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock worth $3,427,000 after purchasing an additional 550,706 shares during the period. Vestal Point Capital LP grew its stake in shares of Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock worth $37,369,000 after purchasing an additional 180,000 shares during the last quarter. Nuveen LLC bought a new stake in shares of Astria Therapeutics in the first quarter worth about $553,000. Finally, Jane Street Group LLC increased its holdings in Astria Therapeutics by 317.3% during the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company's stock valued at $582,000 after purchasing an additional 82,805 shares during the period. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.